Key Therapeutic Uses and Patient Benefits of Волювен

Волювен is used to help manage hypovolemia (low blood volume) and is applied in clinical settings marked by temporary physiological imbalance, specifically where short-term symptomatic assistance is needed to address systemic imbalance.

Supporting Circulatory Stability after Acute Blood Loss

This therapeutic domain is commonly used across conditions presenting with acute episodes of hypovolemia. This medication is applied in situations where additional symptomatic support is needed for conditions involving episodic or fluctuating manifestations of blood loss. It is relevant for acute blood loss from trauma or surgery. The primary benefit contributes to improved comfort during symptomatic periods of low blood volume, which supports general well-being during symptomatic phases.

Addressing Systemic Strain in Acute Episodes

Волювен is considered relevant in contexts involving heightened systemic burden following acute or disruptive episodes. This includes managing the functional stress associated with certain surgical procedures, burns, or injuries. It contributes to easing the overall symptom load, which provides temporary support and helps patients cope more steadily with temporary periods of heightened symptoms and discomfort, assisting with maintaining functional stability.

Quick Fact: Supports Management of Systemic Imbalance

The key benefit helps ease the overall symptom burden during high-stress episodes that lead to physiological imbalance and acute symptoms.

Who Can and Cannot Use Волювен? (Population Eligibility)

The use of Волювен (Hydroxyethyl Starch, HES) is governed by strict regulatory eligibility rules that define who can receive the medicine and who must not. These rules are detailed in official government labeling.

Contraindicated Populations (Must Not Use)

Волювен is strictly prohibited in several critically ill patient populations due to safety risks, including:

• Critically ill adult patients, including those with sepsis.
• Patients with severe liver disease, renal failure with oliguria or anuria, or those receiving dialysis treatment.
• Patients with pre-existing coagulation or bleeding disorders or intracranial bleeding.
• Patients with conditions leading to fluid overload, such as congestive cardiac failure or pulmonary oedema.
• Patients with known hypersensitivity to the active ingredient, HES.

---

Age and Condition Restrictions

Eligibility Group	Regulatory Status
Pediatric Use	Officially not recommended by many agencies due to limited data, despite being indicated for children in some regions.
Renal Impairment	Avoid use in patients with pre-existing renal dysfunction; monitoring and immediate discontinuation upon renal injury are required.
Treatment Duration	Use is strictly limited to the initial volume resuscitation over a maximum of 24 hours.
Pregnancy/Lactation	Use is advised only if the benefit justifies the potential risk to the foetus, and caution is advised in nursing women.

Interactions with other medicines and products

Official regulatory documents from various governmental agencies state that no interactions with other drugs or nutritional products are known to date for Волювен (Hydroxyethyl Starch 130/0.4).

This specific lack of documented interactions means the primary considerations for co-administration relate to the product's inherent physiological effects and formulation rules, rather than specific drug-drug or drug-food exposures.

Interaction Type	Official Regulatory Statement
Drug/Nutritional Products	No interactions with other drugs or nutritional products are known to date.
Inherent Blood Effects	High dosages may cause dilutional effects, resulting in a corresponding decrease in blood components, such as coagulation factors, other plasma proteins, and haematocrit.
Laboratory Test Interference	The concentration of serum amylase can rise temporarily during administration, which is officially noted to interfere with the diagnostic testing for pancreatitis.
Co-administration Rule	Mixing with other medicinal products should generally be avoided; if mixing is necessary in exceptional circumstances, compatibility and hygienic injection/admixture must be ensured.

These statements define the official interaction profile, confirming the absence of known specific drug-agent interactions while highlighting intrinsic effects—dilution and laboratory test interference—that require awareness when the product is used in a clinical setting alongside other treatments.

Colloid-Osmotic Volume Expansion

Волювен (Hydroxyethyl Starch) functions as a synthetic colloid that acts on the fluid balance within the intravascular space. Its large, non-diffusible molecules increase the oncotic pressure of the plasma, drawing fluid from the interstitial spaces into the blood vessels. This physical mechanism results in an increase of circulating blood volume.

---

Modulation of Systemic Hemodynamics

The resulting increase in plasma volume engages a cascade that influences systemic hemodynamic parameters. This volume effect increases cardiac preload and affects parameters related to blood pressure regulation and tissue perfusion. The primary action is focused on physically augmenting circulating volume rather than directly modulating receptor-mediated vascular tone.

---

Enzyme-Controlled Biodegradation and Elimination

The duration of the drug’s action is determined by a mechanism of controlled enzymatic degradation. The specific molecular structure of the HES molecule resists immediate breakdown by the endogenous enzyme alpha-amylase. As the enzyme slowly hydrolyzes the HES into smaller fragments, these are subsequently cleared by renal filtration. This controlled degradation modulates the duration of the volume-increasing effect and determines the clearance profile of the molecules.

How to Use Волювен: Official Administration Guidelines

Волювен is officially designated for administration exclusively via Intravenous (IV) Infusion. This plasma volume expander is supplied as a ready-to-use solution, and no further dilution or preparation is required before use.

Dosing and Administration Protocol

The fundamental principle guiding the use of this solution is the application of the lowest effective dose for the shortest period of time. The infusion must be discontinued as soon as appropriate hemodynamic goals—the desired clinical endpoint—have been achieved.

The dosing schedule includes strict limits on the total amount administered. There is a maximum daily dose based on the patient’s body weight; this ceiling is up to 50 mL/kg per day in certain protocols and restricted to 30 mL/kg per day in others. The precise infusion rate is determined by the rate of blood loss and the patient's individual volume status.

Procedural and Age-Group Rules

The administration requires an initial safeguard step: the initial 10–20 mL must be infused slowly while the patient is under close observation. Before any use, the solution must be visually inspected to ensure it is clear, free of particulate matter, and the container is undamaged.

For pediatric patients, the dosage is adapted to the child’s specific colloid needs, with observed mean doses varying by age group. For patients with renal impairment, dose adjustments are typically required, determined by the patient's status. The use pattern is generally restricted to the initial, acute phase of volume resuscitation, often limited to the first 24 hours in some regions.

Recent Clinical Evidence (Hydroxyethyl Starch 130/0.4)

Voluven, which contains hydroxyethyl starch (HES) 130/0.4, is a plasma volume expander used primarily in the management of hypovolemia (low blood volume), such as during and after surgery. Clinical research has focused extensively on comparing its use against crystalloid solutions (like saline), particularly in critically ill populations.

---

Efficacy in Volume Resuscitation

Studies suggest that HES 130/0.4 can be effective in volume resuscitation, achieving hemodynamic stability (such as restoring blood pressure) with a lower volume of fluid compared to crystalloids. The volume-expanding effect of HES solutions is often observed to be more sustained than that of crystalloids. However, there is no consistent evidence that HES provides a survival benefit over crystalloid solutions in patients needing volume replacement.

---

Safety Concerns in Critically Ill Patients

Recent, large-scale randomized controlled trials (RCTs), including the CHEST and 6S studies, have raised significant safety concerns regarding the use of HES 130/0.4 in certain critically ill patient groups. These findings have led to regulatory restrictions worldwide.

Patient Group	Observed Risk (Compared to Crystalloids)
Sepsis	Increased risk of mortality and need for renal replacement therapy (dialysis).
Critically Ill (General ICU)	Increased risk of acute kidney injury (AKI) and requirement for renal replacement therapy (RRT).

In non-critically ill patients, such as those undergoing elective surgery, the data available is less conclusive regarding the increased risk of acute kidney injury compared to crystalloids, though monitoring of renal function and coagulation is typically maintained as a precaution.

---

Coagulation Effects

Research indicates that HES solutions can affect the blood coagulation system, primarily through hemodilution and impact on specific coagulation factors. While newer generation HES 130/0.4 was developed to minimize these effects compared to older starches, there remains a potential for increased risk of bleeding, especially when used in high doses or during prolonged administration, such as in patients undergoing open heart surgery with cardiopulmonary bypass.

Common questions about Волювен (FAQ)

Q: How long does it take for Волювен to start working after the IV is started?

Studies and official information indicate that the volume-expanding effect is designed to be immediate upon starting the intravenous (IV) infusion. The effect, which helps increase blood volume, is generally reported in clinical studies to be maintained for approximately 4 to 6 hours after a single dose.

---

Q: Does Voluven contain any preservatives that I should be concerned about?

According to the official product information for Волювен (Hydroxyethyl Starch 130/0.4), the solution is explicitly formulated without any preservative. For this reason, any unused portion of the solution should be immediately discarded after the container is opened, according to product handling guidelines.

---

Q: What are the specific signs of a hypersensitivity reaction to Voluven?

While rare, official documents note that signs of a serious hypersensitivity (allergic) reaction can include mild flu-like symptoms, changes in heart rhythm such as a slow heartbeat (bradycardia) or fast heartbeat (tachycardia), or difficulty breathing (bronchospasm). If signs of a reaction are suspected during administration, official guidelines indicate the infusion should be immediately stopped.

---

Q: Can Voluven be used for volume replacement after a severe burn injury?

Voluven is generally intended for volume replacement in acute blood loss (hypovolemia). However, official warnings from some regulatory bodies state that the use of hydroxyethyl starch products, including Волювен, is contraindicated or restricted in certain critically ill populations, which may include patients with severe burn injuries.

---

Q: Does Voluven need to be refrigerated or can it be stored at room temperature?

Official storage rules state that the product should be kept below 25 C (77 F) and must not be frozen. This temperature range allows for storage outside of refrigeration, provided the temperature limit is not exceeded. The solution must always be visually inspected to ensure it is clear and free from particles before use.

---

Q: What is the difference between older and newer versions of Hydroxyethyl Starch?

Волювен contains a newer generation of Hydroxyethyl Starch (HES 130/0.4). Regulatory and scientific data indicate that newer HES products have a lower molecular weight (MW) and lower molar substitution (MS) compared to older versions. Regulatory documents indicate this structural change was implemented to modulate how the body clears the starch, which also influenced its effects on the blood clotting system.

---

Q: Is Voluven the same as the drug Hextend?

The products are considered different due to their specific formulations. While both are plasma volume expanders containing Hydroxyethyl Starch (HES), Voluven uses a specific low molecular weight HES in a sodium chloride solution, whereas Hextend contains a different, higher molecular weight HES in a lactated electrolyte solution.

How to Store and Dispose of Voluven (Hydroxyethyl Starch 130/0.4)

Voluven solution for infusion must be stored and handled according to strict regulatory conditions to ensure its quality and stability.

---

Storage Requirements

Condition	Rule
Temperature	Store below 25 C (77 F).
Prohibition	Do not freeze the solution.
Integrity	The solution must be clear and free from particles, and the container must be undamaged.
Child Safety	Store the medicine out of the reach of children.

---

Stability and Disposal

Voluven is for single use only and contains no antimicrobial preservatives. For this reason, the solution must be used immediately after the container is opened. Any unused portion must be discarded in accordance with local regulations for pharmaceutical waste.